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Patient Advocacy in Cellular Transplantation Therapy:
Addressing Barriers to Hematopoietic Cell
Transplantation
Elizabeth A. Murphy,1 Stacy Stickney Ferguson,1 Nancy Atieno Omondi,1
Lisa C. Getzendaner,2 James L. Gajewski,3 Gary A. Goldstein,4 John R. Wingard,5
J. Douglas Rizzo,6,7 Navneet S. Mahjail8,9Although hematopoietic cell transplantation (HCT) is an effective treatment option for patients with life-
threatening blood, immune system, or genetic disorders, many barriers besides a lack of suitably matched
donors exist and can have an adverse impact on access and outcomes of HCT. In 2008, the National Marrow
Donor Program, through its Office of Patient Advocacy, convened a diverse group of experts and transplan-
tation survivors to identify persistent patient barriers throughout the transplantation process and to make
recommendations for programs and initiatives to address these barriers, including new research opportuni-
ties. This group included transplantation physicians and other health care providers, relevant subject experts,
and representatives from transplantation centers and patient advocacy organizations. Working groups were
formed to identify patient barriers to HCTand to recommend and prioritize initiatives as they relate to the
pretransplantation period, the early posttransplantation period, long-term survivorship, financial issues, and
special populations. This report summarizes the symposium’s deliberations and recommendations to address
persistent patient barriers throughout the transplantation process.
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Despite the tremendous progress in transplanta-
tion over the past 4 decades, persistent barriers to suc-
cessful transplantation still exist. Traditionally, lack of
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6/j.bbmt.2009.08.004barriers to unrelated donor hematopoietic cell trans-
plantation (HCT). Efforts to increase the number
and availability of adult volunteer unrelated donors
in donor registries such as the Be The Match Regis-
trySM of the National Marrow Donor Program
(NMDP), the use of haploidentical family donors,
and the introduction of unrelated umbilical cord blood
(UCB) as a graft source has partially overcome this
problem and substantially increased the probability
that patients who need HCTwill be able to find a suit-
able donor [1]. But, other factors besides the availabil-
ity of a suitable donor can significantly affect a patient’s
suitability for HCT. Consequently, the NMDP com-
missioned a symposium to identify persistent non-
HLA patient barriers throughout the unrelated donor
transplantation process and to make recommendations
for programs and initiatives to address those barriers,
including new research opportunities.SYMPOSIUM ORGANIZATION
The NMDP, through its Office of Patient Advo-
cacy (OPA), convened a diverse group of experts147
Table 1. Important Non-HLA Barriers to Successful HCTand High-Priority Initiatives Needed to Address These Barriers, Along
with Ongoing NMDP Initiatives to Address These Barriers
Barriers Current NMDP Activities High-Priority Initiatives
Pretransplant Working Group
 Lack of early referral
 Donor availability and retention
 Financial clearance for search and
transplantation evaluation
 Education programs and resources for providers
 Outreach to referring physicians
 Targeted recruitment of minority donors
 Donor education using Web-based tools
 Process improvement initiatives
 NMDP customized typing service
 Search Assistance Funds
 Individualized patient financial advocacy
(eg, support for insurance appeals)
 Payor outreach to improve coverage for
search and procurement
 Improve outreach and education efforts
for referring physicians
 Update the registry and remove unavailable
donors
 Promote efforts to increase rapid donor
availability
 Promote awareness and utilization of Search
Assistance Funds
Early Posttransplant Working Group
 Inadequate knowledge about patient/
caregiver needs
 Lack of awareness of available resources
 Inadequate resources for caregivers
 Research to assess patient and caregiver needs
 Patient outreach through direct mail, patient
conferences, NMDP web site, partner ships with
other patient advocacy organizations
 Transplantation center outreach to promote
NMDP patient and caregiver resources
and programs
 Caregiver education and support to address
psychosocial needs
 Collaboration with other patient advocacy
organizations to address caregiver needs
 Increase evaluation of patient and caregiver needs
 Provide support to transplantation centers
to address caregiver concerns
 Promote awareness of existing NMDP and
non-NMDP resources
Survivorship Working Group
 Lack of psychosocial support
 Medical care concerns
 Financial barriers
 Print and online resources for patient
and caregiver education
 Education programs and resources that target
physicians caring for transplantation survivors
 Collaboration with partner programs that
address survivorship, psychosocial issues, and
patient financial needs
 Research to evaluate patient financial needs
 Payor advocacy
 Develop transplantation care summary and
posttransplantation care plan
 Catalog and promote awareness of existing
NMDP and non-NMDP resources
 Develop educational materials to address
specific financial issues
Financial Working Group
 Coverage restrictions
 Lack of patient education
 Fundraising barriers
 Payor outreach and education
 Print and online resources for patients and
caregivers for addressing financial concerns
 Patient education for fundraising
 Increase payor-focused education initiatives
 Expand NMDP financial assistance fund to
offset transplantation expenses
 Promote awareness of existing NMDP and
non-NMDP resources
Special Populations Working Group
 Access to care
 Language, cultural, and literacy barriers
 Geographic barriers
 Medical barriers
 Programs that specifically target populations at
risk (eg, racial minority and rural patients)
 Educational materials that are culturally
and linguistically responsive
 Interpreter services
 Case managers proficient in Spanish
 Conduct research to address disparities in access
to transplantation and posttransplantation care
 Foster collaboration between Network centers
with similar populations
 Create centralized resource to share and
promote services for populations at risk
 National and regional advocacy efforts to address
issues specific to populations at risk
HCT, indicated hematopoietic cell transplantation; NMDP, National Marrow Donor Program.
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providers, relevant subject experts, transplantation
survivors, and representatives from transplant centers
and patient advocacy organizations. Based on their
areas of expertise, participants were assigned to 1 of
5 working groups: pretransplantation, early posttrans-
plantation, survivorship, financial, and special popula-
tions. Although the charter of each of these working
groups focused on unrelated donor transplantation,
the participants were encouraged to also include and
address barriers specific to allogeneic-related and au-
tologous transplantation in their deliberations. Each
group identified specific barriers to HCT and gave
recommendations for new initiatives and programsdesigned to address these barriers (Table 1). The 5
groups conducted their work via conference call meet-
ings over the summer of 2008. Their recommenda-
tions were presented, discussed and prioritized at
a symposium, held in September 2008, inMinneapolis,
Minnesota. Although each working group presented
a substantial list of recommendations, what follows is
a discussion of the recommendations regarding the
high-priority items identified by each group. In many
cases, there is scant scientific evidence on which to
determine the magnitude or prevalence of the barriers
identified, and the high-priority items were so desig-
nated based on their perceived importance by panel-
ists.
Biol Blood Marrow Transplant 16:147-156, 2010 149Barriers to Hematopoietic Cell TransplantationPRETRANSPLANTATIONWORKING GROUP
The pretransplantion working group addressed
barriers encountered by patients, physicians, and
transplantation center health care professionals from
the time of diagnosis to workup for HCT. This phase
is characterized by important steps, including timely
referral, consultation at a transplantation center,
access to a suitably matched donor source, and finan-
cial clearance to proceed to workup for HCT.
Key Barriers and Recommended Initiatives
Timing of Referral for Transplantation
Referring physicians may not always inform
patients of transplantation as an option for treating
their disease or refer patients to transplantation centers
at an optimal time in the disease course. Transplanta-
tion late in the disease process leads to suboptimal
outcomes and fewer patients able to proceed to trans-
plantation because of disease progression, complica-
tions, and/or lack of time to identify a suitable donor
[2-5].
To improve physician/provider-targeted educa-
tion, the working group recommended the following:
1. Increase awareness of and access to NMDP re-
sources for provider education [6], and increase
continuing education programs for physicians and
other providers.
2. Expand promotion of the NMDP’s Referral Out-
reach Program, which supports transplantation
centers in educating their local referring physician
community.
3. Improve web site visibility of the NMDP’s Physi-
cian Resource Center (www.marrow.org/PHYSI-
CIAN) through search engines.
The working group also recognized the need for
patient education. To improve patient-focused educa-
tion, the working group recommended the following:
1. Improve patient awareness and use of educational
materials (eg, the NMDP’s ‘‘Questions to Ask Your
Doctor at the Time of Diagnosis’’ [7]).
2. Conduct patient focus groups to determine effec-
tive ways to streamline delivery of information via
the NMDP web site and to review other patient
education materials.Availability of Unrelated Donors and UCB Units
Donor unavailability can be a significant barrier to
successful transplantation [8-11]. Reasons for donor
attrition include deferment for medical reasons, tem-
porary unavailability, loss of interest in participating
in the program, and inability to locate donors. After
initial confirmation, continued availability of the
donor is also critical when workup is requested. Forpatients being considered for unrelated UCB trans-
plantation, confirmatory typing of units by non-US
CB banks can sometimes have a long turnaround
time and hinder selection of optimal units by trans-
plantation centers.
The working group recommended the following
initiatives:
1. Increase awareness and use of the NMDP Custom-
ized Typing Service. This service reduces search
times by allowing transplantation centers to select
HLA loci, typing resolution, and laboratory turn-
around times for each individual patient.
2. Confirm donor availability before doing high-
resolution typing on previously collected samples,
and reduce the number of days required for direct
donor contact at the time when high-resolution
typing is requested.
3. Develop a continuous performance improvement
process for donor availability.
4. Establish a 14-calendar day turnaround time for
confirmatory typing of UCB units from member
and cooperative banks.
5. Initiate a national project to update and remove
unavailable donors from the registry.Financial Clearance during the
Pretransplantation Phase
Lack of insurance coverage for donor search and
graft procurement can be a significant barrier to
HCT [12]. Lack of funds for patient housing and
travel costs related to the transplantation evaluation
process also can be a barrier to timely transplanta-
tion. Increasing the number of donors on the registry
with high-resolution typing can help eliminate some
steps during the search process and their related
costs, as well as allow for more rapid transplantation
planning.
To address financial barriers to the search and
evaluation process, the working group recommended
the following:
1. Promote and expand Search Assistance Funds
for financially challenged patients through the
NMDP’s Patient Assistance Program, which is
funded by the Be The Match FoundationSM. These
funds can help subsidize the cost of unrelated donor
testing and/or procurement and provide a bridge to
begin donor testing while waiting for insurance
authorization.
2. Expand and promote programs to subsidize patient
costs related to the pretransplantation evaluation
process. For example, the NMDP’s Transplant
Support Assistance Funds can assist with posttrans-
plantation costs not routinely covered by insurance
(eg, temporary housing, meals, travel, insurance
co-pays).
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GROUP
This working group addressed issues faced by pa-
tients in the early posttransplantation period (up to 6
months to 1 year after HCT), which occurs between
the pretransplantation and survivorship phases and is
the most intensive and dynamic phase of the transplan-
tation experience. This phase is characterized by
important transitions: travel to the transplantation
center before the transplantation, setting up a tempo-
rary residence, entry into the transplantation therapy,
transition between the hospital and outpatient clinic
setting at the transplantation center, and discharge
from the transplantation center back to home and local
health care. Patients and their caregivers also are prone
to financial adversity during this period.
Key Barriers and Recommended Initiatives
Inadequate Knowledge of Specific Patient
and Caregiver Needs
There is a lack of existing data regarding early
posttransplantation patient and caregiver needs, spe-
cifically the types of information that are useful, the
manner in which to present this information, and the
barriers to participation in clinical trials. In addition,
little is known about the information needs of commu-
nity physicians regarding this phase of transplantation
therapy. Greater understanding of these requirements
will aid in the development of new resources and
proper utilization of existing materials and resources.
To assess patient and caregiver needs, the working
group recommended the following:
1. Conduct focus groups of patients regarding their
information needs.
2. Conduct focus groups of transplantation center
staff regarding perceived information needs of pa-
tients and caregivers as well as the center’s methods
of delivering patient/caregiver education.
3. Survey transplantation centers to ascertain which
materials they provide to patients and families and
to determine best practices.
4. Support the Bone Marrow Transplant Clinical
Trials Network in a prospective study of psycho-
educational interventions during the early post-
transplantation period.Lack of Information for Patients and Caregivers
Patients and families need more information about
the issues that they face during this phase of transplan-
tation. Such information must be available at multiple
times and be presented via variousmodes to accommo-
date varying language and literacy needs. The NMDP
currently provides a number of resources to support
patients during the search process and the pretrans-plantation phase as well as the survivorship phase,
but few resources address the acute medical complica-
tions and psychosocial issues that arise during the early
posttransplantation phase. Even when such resources
exist, some patients and caregivers are unaware of their
availability.Moreover, individual learning styles differ,
and patients may have an especially difficult time as-
similating information during periods of stress and
crisis. Participation in clinical trials may be daunting
because of the lack of patient materials to explain the
trial. The utilization and effectiveness of available
NMDP patient resources requires further evaluation.
Recommendations to address this barrier include
the following:
1. Improve awareness of existing NMDP materials
and resources among patients and transplantation
centers.
2. Separate children’s resources from adult resources.
3. Develop new materials to facilitate informed deci-
sion making and alleviate patient distress. These
materials should address acute complications and
provide information regarding patient care needs,
coping strategies, and clinical trials specific to the
early posttransplantation period.Inadequate Resources and Support for
Caregivers
Caregivers are under enormous stress, especially in
the early posttransplantation phase [13,14]. Their sup-
port mechanisms often are disrupted if they are far
from home. There is considerable variability among
transplantation centers in terms of resources to address
these issues.
To address caregiver concerns, the working group
recommended the following:
1. Identify key areas of need for caregivers and the
times during the transplantation process when
such information and resources are needed (eg,
medical information, financial help, or emotional
support).
2. Support transplantation centers in the development
of materials and training specifically focused toward
caregivers.
3. Promote the availabilityof existing resources, includ-
ing the Caregivers’ Guide for Bone Marrow/Stem Cell
Transplant developed by nbmtLINK [15].
4. Survey transplantation centers to determine the re-
sources and materials currently available to care-
givers, determine best practices, and facilitate the
spread of such resources and materials to other
centers.
5. Provide information about counseling resources
offered by various organizations (eg, CancerCare).
6. Consider establishing an NMDP counseling
resource.
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This working group focused on barriers to success-
ful long-term survivorship for the time period beyond
6months to 1 year after HCT. Substantial heterogene-
ity exists in long-term follow-up practices among
transplantation centers. The working group noted
that several informational resources already exist
through the NMDP, its partner organizations, and
elsewhere, but that awareness of the available pro-
grams among transplantation centers, health care pro-
fessionals, patients, and caregivers is low and should be
a target area for improvement.
Key Barriers and Recommended Initiatives
Psychosocial Support
Psychosocial concerns faced by survivors and their
caregivers continue for months and years after HCT
[16-18]. These sequelae can include distress, depres-
sion, anxiety, posttraumatic stress disorder, fatigue,
cognitive difficulties, sexual difficulties, and caregiver
burnout.The distress component can comprise such is-
sues as adjustment to life post-HCT, underlying fear of
recurrence and complications, changes in family roles
and relationships, return to work, and social integra-
tion. Although the NMDP and other patient advocacy
organizations provide programs to address these psy-
chosocial sequelae of HCT, awareness of these pro-
grams is limited. Other important barriers include
a lack of knowledge of the prevalence and impact of
psychosocial sequelae by health care providers and
survivors, a lack of tools to assess and guidelines to treat
psychosocial issues, and the absence of centrally lo-
cated survivorship information for patients, caregivers,
and providers. Caregiver-specific issues related to psy-
chosocial support also are frequently overlooked.
Recommendations to address these barriers in-
clude the following:
1. Increase the awareness of the psychosocial sequelae
of HCT in patients, caregivers, and providers.
2. Develop screening tools for patients and providers
to increase recognition of posttransplantation psy-
chosocial survivorship issues, along with specific
guidelines for referral.
3. Develop self-directed interventions and resources
for patients.
4. Provide specific education and support tools for
caregivers, including resources that address psycho-
social issues, their detection, and possible interven-
tion strategies.Medical Care Concerns
Many of the medical barriers experienced during
the survivorship phase for patients, caregivers, and
health care professionals are related to an overallpoor understanding of what occurs during the trans-
plantation process and the importance of appropriate
follow-up. There also may be poor communication be-
tween the transplantation center and the health care
provider responsible for ongoing care after the patient
leaves the transplantation center. Some health care
providers may have little or no experience in caring
for patients after transplantation. In addition, the pa-
tient or provider may not understand which posttrans-
plantation medical problems call for the expertise of
the transplantation center. There also is a general
lack of awareness among patients, caregivers, physi-
cians, and other medical providers of existing
resources that provide recommendations for post-
transplantation care.
Recommendations to address these concerns in-
clude the following:
1. Conduct a survey to determine current transplanta-
tion center practices for long-term care and dis-
charge planning to nontransplantation providers
and determine whether the NMDP can develop
specific materials to facilitate that process.
2. Develop and broadly disseminate educational
materials to address common posttransplantation
problems.
3. Develop an online tool for transplantation pro-
viders, which can create individualized transplanta-
tion care summaries, and from these summaries
generate patient- and condition-specific posttrans-
plantation surveillance and care plans.
4. Promote the use of posttransplantation guidelines
to help facilitate communication between patients
and physicians.Financial Concerns
For patients and caregivers, many of the financial
concerns during the survivorship period involve insur-
ance and insurability and the ability to return to work.
Coping with long-term debt that may have accumu-
lated because of transplantation and related costs can
be a significant stressor for many patients and families.
Specific educational initiatives to address financial
concerns need to be developed through partnering
with other organizations. In addition, educating trans-
plantation centers about these patient resources will
ensure improved utilization of available resources.
To address financial barriers to successful long-
term survivorship, the working group recommended
the following:
1. Create a catalog of programs that provide financial
assistance and increase the awareness of these pro-
grams among patients and transplantation centers.
2. Develop a program to educate insurers and em-
ployers about the financial burdens of transplanta-
tion survivorship.
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cial support organizations.
4. Develop and conduct training for transplantation
center personnel about available financial assistance
resources.
5. Explore partnerships to develop educational mate-
rials regarding specific financial issues, such as pre-
existing conditions and changing insurance plans or
employers.FINANCIALWORKING GROUP
Financial barriers can be varied and considerable. A
significant number of patients undergoing HCT incur
medical debt and face ongoing financial challenges
throughout the transplantation process. Nonmedical
costs and other out-of-pocket expenses (including
co-pays for prescription medications) associated with
transplantation can add to patient and caregiver finan-
cial stress [14]. Somepatients arenot able to successfully
rejoin the workforce because of long-term posttrans-
plantation complications. This working group also rec-
ognized that the transplantation process can have a
significant financial impact on caregivers as well.
Key Barriers and Recommended Initiatives
There is a lack of patient education regarding
insurance, finances, and employment rights
Educating patients, caregivers, and the transplan-
tation community about the financial impact of trans-
plantation is important to allow patients to plan for
HCT-related expenses. The OPA currently provides
several tools, including the Financial Calculator and
educational resources, to help patients and caregivers
understand their insurance coverage and prepare for
the financial implications of HCT. The OPA also of-
fers financial help through the Patient Assistance Pro-
gram and can help locate other financial resources;
however, these resources are largely underutilized, be-
cause not all patients and transplantation centers are
aware of their availability.
To increase the dissemination of existing resources
that provide information about these issues, the work-
ing group recommended the following:
1. Expand OPA financial presentations at existing
transplantation conferences (eg, NMDP Council
Meeting, BMT Tandem Meetings, Association of
Oncology Social Work conferences).
2. Host web-based interactive seminars to disseminate
OPA materials and educate various transplantation
center personnel about patients’ financial needs and
available programs.
3. Develop a web-based central information portal for
patients and transplantation center personnel to
learn about non-NMDP assistance programs.Coverage Restrictions
Insurance and Medicare coverage restrictions rep-
resent a major barrier to transplantation. Specific lim-
itations can include lack of coverage for specific
diagnoses, donor search or procurement limits, insuf-
ficient dollar-based transplantation benefit maxi-
mums, and denials for cutting-edge treatments (ie,
unreasonable, experimental, or investigational policy
language). Nationally, the NMDP engages payors
through activities that focus on appropriate coverage
and reimbursement for transplantation-related ex-
penses and educates them about the indications for,
processes in, and outcomes of HCT. The NMDP
may need to enhance its payor education efforts to ad-
dress these barriers.
Specific recommendations directed at the
NMDP’s payor education efforts include the follow-
ing:
1. Conduct a multipronged, payor-focused education
initiative to include transplantation-specific benefit
caps, noncoverage or caps on search charges, ex-
pansion of benefits for relocation, transportation,
and donor/caregiver expenses.
2. Direct education and communication to commer-
cial insurance companies, America’s Health Insur-
ance Plans trade association, Self-Insurance
Institute of America, and transplantation network
contracting companies.Fundraising Barriers
Fundraising can be an important tool to allow pa-
tients to meet some of the financial costs of transplan-
tation. Our experience indicates that the majority of
patients do not engage in fundraising efforts, however.
Patients may attach a stigma to fundraising or asking
for help. In addition, transplantation centers do not
have the resources to assist patients in their fundraising
efforts.
Recommendations to address this barrier include
the following:
1. The OPA should continue to facilitate patient con-
tact with nonprofit organizations that assist in fund-
raising efforts.
2. Increase the NMDP’s per-patient assistance level
for donor searches to allow more searches.
3. Partner with other organizations to create a grant
program that wouldmatch a patient’s own fundrais-
ing efforts.Limited Legislative Advocacy
Several opportunities exist where government ac-
tion could address financial barriers to transplantation.
Recommended national government advocacy efforts
include the following:
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Society of Blood and Marrow Transplantation to
address Medicare’s lack of HCT coverage for mye-
lodysplastic syndrome (MDS).
2. Initiate efforts to address Medicare’s lack of cover-
age for allogeneic HCT for Hodgkin and non-
Hodgkin lymphoma (HL, NHL).
3. Educate Congress and the Office of Personnel
Management regarding the need to allow the Fed-
eral Employee Program’s insurance policy to cover
unrelated donor searches.
4. Coordinate efforts to enact federal legislation man-
dating coverage for qualifying cancer clinical trials.
5. Consider advocating for a mandate that would re-
quire insurance companies to cover donor searches
and procurement charges if transplantation is a cov-
ered benefit.SPECIAL POPULATIONSWORKING GROUP
The transplantation experience can be particularly
challenging to patients belonging to medically under-
served communities. These patients frequently en-
counter barriers that substantially limit their access
to transplantation as a treatment option and/or issues
that affect the quality of life posttransplantation.
These ‘‘special’’ populations include racial and ethnic
minorities, persons with limited English proficiency
or health literacy, residents of certain geographic re-
gions (eg, rural), high-risk age groups (eg, pediatric,
adolescent/young adult, over the age of 50 years), the
uninsured and underinsured, and non-US citizens
and residents. Within the definition of special popula-
tions, this working group also included caregivers as
a distinctly underserved population, because they
have unique care and support needs.Key Barriers and Recommended Initiatives
The working group identified 4 domains that are
barriers to successful transplantation in medically un-
derserved populations: (1) barriers that prevent access
to care; (2) language, cultural, and literacy barriers; (3)
environmental and geographic barriers; and (4) genetic
andmedical barriers. Special populations encounterdis-
proportionate access barriers, including no or limited
insurance coverage for transplantation and follow-up
care, insufficient financial resources for medical and
nonmedical expenses associated with transplantation,
and lackof a committed caregiver [19].Racial and ethnic
minority populations are more likely to be uninsured or
underinsured. [20,21].There also is a need for culturally
appropriate approaches for outreach and education of
special populations. Patients residing in rural areas
face many significant challenges in accessing adequate
health care compared with those living in urban areas[22]. Issues specific to rural patients include isolation;
limited access to health care services, employer-pro-
vided health insurance, and public transportation; and
lower socioeconomic status. Individuals of certain eth-
nic backgrounds disproportionately represent both the
most commonly matched and the most unique HLA
tissue types needed for HCT. High levels of HLA
diversity pose a significant challenge for populations at
risk, because a patient is most likely to receive a HCT
using a donor fromhis or her own racial or ethnic group.
To address the barriers encountered by under-
served populations, this working group recommended
a 2-track approach: (1) Ensure that underserved popu-
lations are considered in initiatives that address
broader access issues, and (2) develop initiatives to ad-
dress the barriers for populations at risk. Strategies to
address these barriers require initiatives within the
NMDP and at the local, regional, and national levels.
At the national level, the NMDP should increase
advocacy efforts for expanded resources and programs
that directly impact access to transplantation for pa-
tients and families from underserved populations, as
well as those who work on their behalf. Specific key
recommendations include the following:
1. Create special interest groups for other medical
specialties (eg, internal medicine) who are inter-
ested in better supporting transplantation patients
from their population group.
2. Expand existing and develop new communication
strategies with national, state, and federal agencies
and organizations (eg, Centers for Medicare and
Medicaid Services).
3. Identify successful incentives for partnership, espe-
cially at the points of diagnosis and referral to
a transplantation center.
To improve coordination and communication of
available programs, resources, and materials among
NMDP network centers and those who work on behalf
of special populations, the working group recommen-
ded the following:
1. Create guidelines and resources for specific popula-
tions, such as specialized training and resources re-
garding transplantation for rural and home health
providers.
2. Create a central resource to share and promote ma-
terials and services.
3. Increase support for onsite visits by NMDP staff to
transplantation centers that serve special popula-
tions to facilitate the delivery of existing tools, tech-
nical assistance, and services.
4. Expand outreach to key professional audiences.
The NMDP should support local and regional
initiatives that address barriers to transplantation that
have a disproportionate impact on the access to
transplantation for special populations. Specific
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thefollowing:
1. Increase access to or create local patient navigation
resources.
2. Provide data and policy analysis support to develop
tailored outreach and support plans for the specific
special populations local to individual transplanta-
tion centers.
3. Share special populations data to allowNMDPnet-
work centers and agencies with like populations to
work collaboratively.
4. Create professional education resources for trans-
plantation and evidence-based strategies to support
special populations.SUMMARYOF RECOMMENDATIONS
After the Chair of each working group presented
the group’s recommendations, the symposium at-
tendees voted to prioritize these recommendations.
Top priorities for the NMDP to address non-HLA
barriers to HCT, in order of importance, include (1)
increase awareness of existing HCT resources and ser-
vices, (2) develop public policy information and educa-
tion programs to promote access to HCT, (3) conduct
a transplantation center needs assessment to determine
their level of awareness and use of NMDP resources
and services to assist HCT patients and caregivers, (4)
conduct a patient needs assessment to determine effec-
tive ways to streamline the delivery of HCT informa-
tion and obtain feedback on NMDP resources and
services, (5) expand NMDP efforts to improve reten-
tion of donors in theBeTheMatchRegistry, (6) expand
the NMDP’s Patient Assistance Program to provide
financial grants earlier in the pretransplantation phase,
(7) increase support for NMDP staff to conduct onsite
visits of transplantation centers, and (8) expand promo-
tion of the Referral Outreach Program.
Based on the symposium’s prioritized recommen-
dations, the NMDP instituted a special task force to
identify metrics to quantify the effectiveness and effi-
ciency of initiatives aimed at resolving or mitigating
these barriers. In addition to this task force, the
NMDP Board of Directors authorized its Patient-
Focused Initiatives Committee to oversee the imple-
mentation of specific symposium initiatives and
monitor their effectiveness. The NMDP also will con-
tinue to collaborate with other organizations to elimi-
nate health disparities; for instance, it is a named
partner in the National Institutes of Health’s Strategic
Plan on Reducing Health Disparities.ACKNOWLEDGMENTS
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